Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study
GLP-1RA treatment was safe and associated with reduced risks of cardiovascular and psychiatric comorbidities, as well as lower mortality in patients with psoriasis, with risk reductions markedly higher than in cohorts without psoriasis. Physicians should consider this drug class for patients with psoriasis and comorbid obesity or diabetes.
Authors
- Gema Hernández (ORCID: https://orcid.org/0000-0003-4832-455X)
- Ralf Joachim Ludwig (ORCID: https://orcid.org/0000-0002-1394-1737)
- Henner Zirpel (ORCID: https://orcid.org/0000-0003-0053-4312)
- Evelyn Gaffal (ORCID: https://orcid.org/0000-0002-4639-9841)
- Khalaf Kridin (ORCID: https://orcid.org/0000-0001-9971-9151)
- Henning Olbrich (ORCID: https://orcid.org/0000-0003-0863-7148)
- Diamant Thaçi (ORCID: https://orcid.org/0000-0001-8513-550X)
- Christian D. Sadik (ORCID: https://orcid.org/0000-0001-6701-048X)
Institutions
- Bar-Ilan University (IL)
- Western Galilee Hospital (IL)
- University Hospital Schleswig-Holstein (DE)
- TriNetX (United States) (US)
- Universidad Politécnica de Madrid (ES)
- University of Lübeck (DE)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1093/bjd/ljaf346
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.39